Targeting T and B lymphocytes with radiolabeled antibodies for diagnostic and therapeutic applications

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 6, 2010, Pages 654-676

  Malviya, G ^a,b   Galli, F ^a   Sonni, I ^a   Pacilio, M ^a   Signore, A ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antigens, CD; B lymphocytes; Inflammation

Indexed keywords

123C 3; BASILIXIMAB; DACLIZUMAB; HUMAN IMMUNOGLOBULIN TC 99M; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 C 14; INTERLEUKIN 2 I 123; INTERLEUKIN 2 I 125; INTERLEUKIN 2 I 131; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 S 35; INTERLEUKIN 2 TC 99M; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY CD3 TC 99M; MONOCLONAL ANTIBODY CD4 TC 99M; MONOCLONAL ANTIBODY ERIC 1 I 131; MONOCLONAL ANTIBODY ERIC 1 Y 90; MONOCLONAL ANTIBODY NCAM I 131; NY 3 D11; OKT 3; OKT 4; RADIOPHARMACEUTICAL AGENT; STEROID; TAC ANTIBODY BI 212; TAC ANTIBODY FV FRAGMENT F 18; TAC ANTIBODY FV FRAGMENT I 125; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB; VISILIZUMAB TC 99M;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ANTIBODY LABELING; AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BINDING AFFINITY; BONE METASTASIS; CANCER SURGERY; CAROTID ATHEROSCLEROSIS; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG ACCUMULATION; DRUG DISTRIBUTION; GAMMA DELTA T LYMPHOCYTE; GLIOBLASTOMA; GLIOMA; GOUT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; IMMUNOSCINTIGRAPHY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE LABELING; JOINT SCINTISCANNING; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT REJECTION; KIDNEY SCINTISCANNING; LEUKEMIA; LIVER METASTASIS; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MEMORY CELL; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOARTHRITIS; PLASMA CELL; PSORIATIC ARTHRITIS; RADIOIMMUNOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T CELL LEUKEMIA; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; B-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; ISOTOPE LABELING; MOLECULAR IMAGING; RADIOISOTOPES; RADIOPHARMACEUTICALS; T-LYMPHOCYTES;

EID: 79953121951     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. WuChianelli M, Boerman OC, Malviya G, Galli F, Oyen WJG, Signore A. Receptor binding ligands to image infection. Curr Pharm Design 2008;14:3316-25.
2. Malviya G, de Vries EFJ, Dierckx RA, Signore A. Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Bra Arch Bio Tech 2008;50:1-13.
3. Malviya G, Lagàna B, Signore A, Dierckx RA. Radiolabeled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Design 2008;14:2401-14.
4. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009;228:9-22.
5. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009;229:88-100.
6. von Boehmer H, Kisielow P, Kishi H, Scott B, Borgulya P, Teh HS. The expression of CD4 and CD8 accessory molecules on mature T cells is not random but correlates with the specificity of the alpha beta receptor for antigen. Immunol Rev 1989;109:143-51. (Pubitemid 19151498)
7. Sallusto F, Lanzavecchia A. Heterogeneity of CD41 memory T cells: functional modules for tailored immunity. Eur J Immunol 2009;39:2076-82.
8. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al. Foxp31 CD251 CD41 natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27. (Pubitemid 44116697)
9. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp31 regulatory T cells: more of the same or a division of labor? Immunity 2009;30:626-35.
10. Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 2002;169:1236-40. (Pubitemid 34809164)
11. Sen J, Bossu P, Burakoff SJ, Abbas AK. T cell surface molecules regulating noncognate B lymphocyte activation. Role of CD2 and LFA-1. J Immunol 1992;148:1037-42.
12. Vacca A, Buchegger F, Carrel S, Mach JP. Imaging of human leukemic T-cell xenografts in nude mice by radiolabeled monoclonal antibodies and F(ab′)2 fragments. Cancer 1988;61:58-67. (Pubitemid 18023111)
13. Langley RG, Papp K, Bissonnette R, Toth D, Matheson R, Hultquist M, White B. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol 2010;49:818-28.
14. Pruett TL, McGory RW, Wright FH, Pescovitz MD, Yang H, McClain JB. Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients. Transplant Proc 2009;41:3655-61.
15. Adkins D, Ratanatharathorn V, Yang H, White B. Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease. Transplantation 2009;88:198-202.
16. Martins FPP, Gutfilen B. Estudo da marcação do anticorpo monoclonal OKT3 com tecnécio-99m: aplicações clinicas. Radiologia Brasileira 2002;35:286.
17. Martins FPP, Souza SAL, Gonçalves RT, Fonseca LMB, Gutfilen B. Preliminary Results of [99mTc]OKT3 Scintigraphy to Evaluate Acute Rejection in Renal Transplants. Transplantation Proceedings 2004;36:2664-7.
18. Martins FPP, Gutfilen B, DE Souza SAL, DE Azevedo MNL, Cardoso LR, Fraga R et al. Monitoring rheumatoid arthritis synovitis with 99mTc-anti-CD3. Br J Radiol 2008;81:25-9. (Pubitemid 351154771)
19. Marcus C, Thakur ML, Huynh TV, Louie JS, Leibling M, Minami C et al. Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nucl Med Commun 1994;15:824-30.
20. Lopes FPPL, de Azevedo MNL, Marchiori E, da Fonseca LMB, de Souza SAL BGutfilen. Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases. Rheumatology 2010;49:933-9.
21. Woodle ES, Xu D, Zivin RA, Auger J, Charette J, O'Laughlin R et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68:608-16.
22. Cole MS, Stellrecht KW, Shi JD, Homola M, Hsu DH, Anasetti C et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999;68:563-71. (Pubitemid 29416634)
23. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995;60:847-53.
24. Cole M, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol 1997;159:3613-21. (Pubitemid 127482121)
25. Trajkovic V. Nuvion Protein Design Labs. Curr Opin Investig Drugs 2002;3:411-4.
26. Dingermann T, Zündorf I. Macromolecular Immunosuppressants. Biotechnol J 2006;1:47-57.
27. Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc g receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995;155:1544-55.
28. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998;160:4841-9.
29. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H et al. Systemic reaction to the anti-T cell mAb OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989;320:1420-1. (Pubitemid 19138943)
30. Kan EAR, Wright SD, Weite K, Wang CY. Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol 1986;98:181-7. (Pubitemid 16112024)
31. Clement LT, Tilden AB, Dunlap NE. Analysis of the monocyte Fc receptors and Ab-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 Abs. J Immunol 1985;135:165-71. (Pubitemid 15010513)
32. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr Transplant 2003;7(Suppl 3):19-31.
33. Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C et al. Radiolabeled Humanized Anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes. J Nucl Med 2009;50:1683-91.
34. Abrams MJ, Juweid M, ten Kate CI, Schwartz DA, Hauser MM, Gaul FE et al. Technetium-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8.
35. Pohlers D, Schmidt-Weber CB, Franch A, Kuhlmann J, Bräuer R, Emmrich F et al. Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-κB binding activity and TNF-α secretion of T cells. Arthritis Res 2002;4:184-9.
36. Reddy MP, Kinney CAS, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P et al. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4. J Immunol 2000;164:1925-33.
37. Becker W, Emmrich F, Horneff G, Burmester G, Seiler F, Schwarz A et al. Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies. Eur J Nucl Med 1990;17:156-9.
38. Kinne RW, Becker W, Schwab J, Horneff G, Schwarz A, Kalden JR et al. Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun 1993;14:667-75.
39. Kinne RW, Becker W, Schwab J, Schwarz A, Kalden JR, Emmrich E et al. Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies. Eur J Nucl Med 1994;21:176-80.
40. 111In-labeled anti-CD4 monoclonal antibody. Proc Natl Acad Sci USA 1996;93:7460-3.
41. Kinne RW, Becker W, Simon G, Paganelli G, Kinne EP, Woiski A et al. Joint uptake and body distribution of a technetium-99m-labeled anti-rat-CD4 monoclonal antibody in rat adjuvant arthritis. J Nucl Med 1993;34:92-8.
42. Davis CB, Garver EM, Kwok DC, Urbanski JJ. Disposition of metabolically radiolabeled CE9.1-A macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4. Drug Metabol Disp 1996;24:1032-7.
43. Liberatore M, Clemente M, Iurilli AP, Zorzin L, Marini M, Di Rocco E et al. Scintigraphic evaluation of disease activity in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 1992;19:853-7.
44. Spertini F, Stohl W, Ramesh N, Moody C, Geha RS. Induction of human T cell proliferation by a monoclonal antibody to CD5. J Immunol 1991;146:47-52.
45. Calvo J, Places L, Padilla O, Vila JM, Vives J, Bowen MA, Lozano F. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand. Eur J Immunol 1999;29:2119-29.
46. Vallera DA, Schmidberger H, Buchsbaum DJ, Everson P, Snover DC, Blazar BR. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier. Cancer Res 1991;51:1891-7.
47. Schmidberger H, Buchsbaum DJ, Blazar BR, Everson P, Vallera DA. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4. Cancer Res 1991;51:1883-90.
48. 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998;4:2691-700.
49. 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum B 1990;17:201-7.
50. Prescribing information. Zenapax (daclizumab). Roche, NJ; 2005.
51. Mottershead M, Neuberger. Daclizumab. Expert Opin Biol Ther 2007;7:1583-96.
52. Mertelsmann R, Trepel M. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 2007;67:3518-23.
53. Prescribing information. Simulect (basiliximab). Novartis, NJ; 2003.
54. Binder M, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, Sundararajan S et al. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981;126:1398-403.
55. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86:10029-33.
56. Wu C, Jagoda E, Brechbiel M, Webber KO, Pastan I, Gansow O et al. Biodistribution and Catabolism of Ga-67-Labeled AntiTac dsFv Fragment. Bioconjugate Chem 1997;8:365-9.
57. Kobayashi H, Yoo TM, Drumm D, Kim MK, Sun BF, Le N et al. Improved biodistribution of 125I-labeled anti-tac disulfide-stabilized fv fragment by blocking its binding to the α subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-tac IgG. Cancer Res 1997;57:1955-61.
58. 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 2006;66:8227-32.
59. Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994;54:4362-70.
60. Choi CW, Lang L, Lee JT, Webber KO, Yoo TM, Chang HK et al. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res 1995;55:5323-9.
61. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth factor of T lymphocytes from normal human bone marrow. Science 1976;193:1007-9.
62. Miyajima A, Miyatake S, Schreurs J, De Vries J, Arai N, Yokota T et al. Coordinate regulation of immune and inflammatory responses by T cell-derived lymphokines. FASEB J 1988;2:2462-73.
63. Muraguchi A, Kehrl JH, Longo DL, Volkman DJ, Smith KA, Fauci AS. Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med 1985;161:181-97.
64. Smith KA. Interleukin-2. Curr Opin Immunol 1992;4:271-6.
65. Smith KA. Interleukin-2: inception, impact and implications. Science 1988;240:1169-76.
66. Koths K, Halenbech R. Pharmacokinetic studies on 35S-labelled recombinant interleukin-2 in mice. Cellular and molecular biology of lymphokines: International Lymphokine Workshop 1984, at Schloss Elmau, West Germany. In: Sorg C, Schimpl A, Landy M, editors. Orlando, FL: Academic Press; 1985. p. 779-83.
67. Robb RJ, Mayer PC, Garlick R. Retention of biological activity following radioiodination of human interleukin-2: comparison with biosynthetically labelled growth factor in receptor binding assay. J Imuunol Meth 1985;81:15-30.
68. Gennuso R, Spigelman MK, Vallabhajosula S, Moore F, Zappulla R, Nieves J et al. Systemic biodistribution of radioiodinated interleukin-2 in the rat. J Biol Resp Mod 1989;8:375-84.
69. 14C labelled recombinant human interleukin-2 in the rat. Lymphokine Cytokine Res 1992;11:229.
70. Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria C, Chianelli M et al. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med 2004;45:1647-52.
71. Loose D, Signore A, Bonanno E, Vermeersch H, Dierckx R, Deron P et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biother Radiopharm 2008;23:25-33.
72. Loose D, Signore A, Staelens L, Bulcke KV, Vermeersch H, Dierckx RA et al. (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. Eur J Nucl Med Mol Imaging 2008;35:281-6.
73. Renard V, Staelens L, Signore A, Van Belle S, Dierckx RA, Van De Wiele C. Iodine-123-interleukin-2 scintigraphy in metastatic hypernephroma: a pilot study. Q J Nucl Med Mol Imaging 2007;51:352-6.
74. Annovazzi A, Biancone L, Caviglia R, Chianelli M, Capriotti G, Mather SJ et al. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003;30:374-82.
75. Annovazzi A, Bonanno E, Arca M, D'Alessandria C, Marcoccia A, Spagnoli LG et al. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006;33:117-26.
76. Signore A, Picarelli A, Chianelli M, Biancone L, Annovazzi A, Tiberti C et al. 123I-Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity. J Pediatric Endocrinol Metab 1996;9(Suppl 1):139-44.
77. Signore A, Picarelli A, Annovazzi A, Britton KE, Grossman AB, Bonanno E et al. 123I-interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 2003;24:305-16.
78. Barone R, Chianelli M, Procaccini E, Chianelli M, Bottoni U, Panetta C et al. 99mTc-IL-2 scintigraphy in patients with cutaneous melanoma: detection of lymphocytic infiltration. (abstract) Eur J Nucl Med 1998;25;896.
79. Lucia P, Parisella MG, Danese C, Bruno F, Manetti LL, Capriotti G et al. Diagnosis and followup of Takayasu's arteritis by scintigraphy with radiolabeled interleukin 2. J Rheumatol 2004;31:1225-7.
80. 99mTc-IL2 scintigraphy in autoimmune thyroid diseases. (abstract) Eur J Nucl Med 1998;25:977.
81. 125I] recombinant human interleukin-2 in cynomolgus monkeys. Drug Metabol Dispo 1995;23:904-9.
82. Lefrancois L. Expression of carbohydrate differentiation antigens during ontogeny of the murine thymus. J Immunol 1987;139:2220-9.
83. Coffman RL, Weissman IL. B220: a B cell-specific member of th T200 glycoprotein family. Nature 1981;289:681-3.
84. Dalchau R, Fabre JW. Identification with a monoclonal antibody of a predominantly B lymphocyte-specific determinant of the human leukocyte common antigen. Evidence for structural and possible functional diversity of the human leukocyte common molecule. J Exp Med 1981;153:753-65.
85. Lefrancois L, Thomas ML, Bevan MJ, Trowbridge IS. Different classes of T lymphocytes have different mRNAs for the leukocyte-common antigen, T200. J Exp Med 1986;163:1337-42.
86. Arthur RP, Mason D. T cells that help B cell responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. J Exp Med 1986;163:774-86.
87. Spickett GP, Brandon MR, Mason DW, Williams AF, Woollett GR. MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen. J Exp Med 1983;158:795-810.
88. Morimoto C, Letvin NL, Boyd AW, Hagan M, Brown HM, Kornacki MM, Schlossman SF. The isolation and characterization of the human helper inducer T cell subset. J Immunol 1985;134:3762-9.
89. Rudd CE, Morimoto C, Wong LL, Schlossman SF. The subdivision of the T4 (CD4) subset on the basis of the differential expression of L-C/T200 antigens. J Exp Med 1987;166:1758-73.
90. Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM et al. Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice. Cancer Biother Radiopharm 2003;18:133-45.
91. Vallera DA, Sicheneder AR, Taras EP, Brechbiel MW, Vallera JA, Panoskaltsis-Mortari A, Burns LJ. Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody. Cancer Biother Radiopharm 2007;22:488-500.
92. Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood 2009;113:5905-10.
93. Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006;47:1335-41.
94. Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 2009;114:1226-35.
95. Lin Y, Pagel JM, AxworthyD, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66:3884-92.
96. Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res 2009;69:185-92.
97. Kwa HB, Verhoeven AH, Storm J, van Zandwijk N, Mooi W, Hilkens J. Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3. Cancer Immunol Immunother 1995;41:169-74.
98. Ornadel D, Ledermann JA, Eagle K, Pedley RB, Boxer G, Ward SE et al. Biodistribution of a radiolabeled monoclonal anti-body NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer. Br J Cancer 1998;77:103-9.
99. Papanastassiou V, Pizer BL, Coakham HB, Bullimore J, Zananiri T, Kemshead JT. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993;67:144-51.
100. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995;34:121-31.
101. Hosono MN, Hosono M, Mishra AK, Faivre-Chauvet A, Gautherot E, Barbet J et al. Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer. Ann Nucl Med 2000;14:173-9.
102. Arimura Y, Koda T, Kishi M, Kakinuma M. Mouse HLA-DPA homologue H2-Pα: a pseudogene that maps between H2-Pb and H2-Oα. Immunogenetics 1996;43:152-5.
103. Sønderstrup G, McDevitt HO DR, DQ, and you: MHC alleles and autoimmunity. J Clin Invest 2001;107:795-6.
104. Cosgrove D, Bodmer H, Bogue M, Benoist C, Mathis D. Evaluation of the functional equivalence of major histocompatibility complex class II A and E complexes. J Exp Med 1992;176:629-34.
105. Lewis JP, DeNardo GL, DeNardo SJ. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 1995;14:115-20.
106. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB et al. Maximum-tolerated dose, toxicity and efficacy of 131I-Lym-1 antibody for fractionated radio-immunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246-56.
107. DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 1998;13:239-54.
108. O'Donnell RT, DeNardo GL, Kukis DL, et al. 67Copper-2-iminothiolane-6-[p- (bromocetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:3330s-6s.
109. DeNardo GL, Kroger LA, Mirick GR, Lamborn KR, DeNardo SJ. Analysis of antiglobulin (HAMA) response in a group of patient with B-lymphocytic malignancies treated with 131I-Lym-1. Int J Biol Markers 1995;10:67-74.
110. DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 1998;13:1-12.
111. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res 2007;67:5921-8.
112. Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood. 2009;113:4903-13.
113. DeNardo GL, Hok S, Van Natarajan A, Cosman M, DeNardo SJ, Lightstone FC et al. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol. 2007;31:729-40.
114. Zola H, Beare A. 1D09C3, an mAb specific for MHC-II. Curr Opin Mol Ther 2008;10:68-74.
115. 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression. Mol Imaging Biol 2010;DOI:10.1007/s11307-010-0407-9.
116. Otero DC, Rickert RC. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transitino. J Immunol 2003;171:5921-30.
117. Vervoordeldonk SF, Heikens J, Goedemans WT, Merle PA, von dem Borne AE, van Royen EA et al. 99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma. Cancer Immunol Immunother 1996;42:291-6.
118. Multani PS, O'Day S, Nadler LE, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998;4:2599-604.
119. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853-8.
120. Vervoordeldonk SF, Merle PA, van Leeuwen EF, von dem Borne AE, Slaper-Cortenbach IC. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer 1994;73(3 Suppl):1006-11.
121. Pizer B, Papanastassiou V, Hancock J, Cassano W, Coakham H Kemshead J. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haematol 1991;77:466-72.
122. Pizer BL, Kemshead JT. The potential of targeted radiotherapy in the treatment of central nervous system leukaemia. Leuk Lymphoma 1994;15:281-9.
123. 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002;16:60-6.
124. + B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD 19 Monoclonal Antibodies. J Nucl Med 2010;44:1105-12.
125. Tedder TF, McIntyre G, Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol 1988;25:1321-30.
126. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
127. Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 1988;168:1205-10.
128. Rituxan® (Rituximab), package insert. Genentech Inc., San Francisco, CA; 2007.
129. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
130. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
131. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule Bl is functionally linked with B-cell activation and differentiation. J Immunol 1985;135:973-9.
132. Dorner, T, Rumester, G. The role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Op Rheum 2003;15:246-52.
133. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol/Hematol 2005;54:11-29.
134. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer 2001;85:1619-23.
135. Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from Rituximab. Sci STKE 2004;(241):30.
136. Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ. 99mTc-rituximab radiolabeled by photo-activation: a new non-Hodgkin's lymphoma imaging agent. Eur J Nucl Med 2006;33:53-9.
137. Stalteri MA, Mather SJ. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photo activation. Eur J Nucl Med 1996;23:178-87.
138. Wang XJ, Lin BH, Yang Z, Ouyang T, Li JF, Xu B et al. Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient. Zhonghua Zhong Liu Za Zhi (Chinese J Oncol) 2006;28:200-3.
139. Lindén O, Kurkus J, Garkavij M, Cavallin-Ståhl E, Ljungberg M, Nilsson R et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labelled rituximab in patients with refractory B-cell lymphoma. Can Biother Radiopharma 2005;20:457-66.
140. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007;48:1767-76.
141. 99mTc-labelled rituximab for imaging CD20+ve B-lymphocytes in inflammatory autoimmune disease patients: our imaging experience. Q J Nucl Med Mol Imaging 2010;54(Suppl 2):11.
142. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997;15:481-504.
143. Cesano A, Gayko U, Brannan C, Kapushoc H, Fields SZ, Perkins SL Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for target immunotherapy. Blood 2002:350a.
144. Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005;88:1-50.
145. Steinfeld SD, Youinou P. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 2006;6:943-9.
146. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB et al Construction and characterization of a humanized, internalizing B cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32:1413-27.
147. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for malignancies. Experimental Hematology 2008;36:755-68.
148. Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009;67:311-21.
149. Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 2002;17:689-97.
150. Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infectious Diseases 2001;1:326-33.
151. Malviya G, Conti F, Chianelli M, Scopinaro F, Dierckx RA, Signore A. Molecular imaging of rheumatoid arthritis by radiolabeled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 2010;37:386-98.